Telomir Pharmaceuticals, Inc. (TELO)

Telomir Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	0.83	0	0	-
Cash & Short-Term Investments	0.83	0	0	-
Cash Growth	33939.07%	-13.25%	-	-
Prepaid Expenses	0.08	0	-	-
Other Current Assets	0.13	0.43	0.05	-
Total Current Assets	1.04	0.44	0.05	-
Long-Term Deferred Charges	-	4.34	-	-
Total Assets	1.04	4.77	0.05	-
Accounts Payable	0.51	0.71	0.4	0.02
Short-Term Debt	0.09	0.63	0.58	0.12
Total Current Liabilities	0.6	1.34	0.99	0.14
Total Liabilities	0.6	1.34	0.99	0.14
Additional Paid-In Capital	28.14	17.5	0.06	0.06
Retained Earnings	-27.7	-14.06	-0.99	-0.14
Comprehensive Income & Other	-	-	-	-0.06
Shareholders' Equity	0.44	3.44	-0.94	-0.14
Total Liabilities & Equity	1.04	4.77	0.05	-
Total Debt	0.09	0.63	0.58	0.12
Net Cash (Debt)	0.74	-0.63	-0.58	-0.12
Net Cash Per Share	0.03	-0.02	-0.02	-
Filing Date Shares Outstanding	29.61	29.61	27.1	-
Total Common Shares Outstanding	29.61	28.61	26.83	-
Working Capital	0.44	-0.9	-0.94	-0.14
Book Value Per Share	0.01	0.12	-0.03	-
Tangible Book Value	0.44	3.44	-0.94	-0.14
Tangible Book Value Per Share	0.01	0.12	-0.03	-

Source: S&P Capital IQ. Standard template. Financial Sources.